GlassScriptPhysician profile
Henry C Miller
NPI 1033529599
$5,413.61
in general payments reported to CMS, 2019-2025
29 companies · $5,414 in 2025
The $5,414 reported for 2025 was more than what 98% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $5,414.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,850 · Food and Beverage: $2,564.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,850.00 |
| Food and Beverage | $2,563.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Plasma INC. | $2,850.00 | 2025 | |
| Abbvie INC. | $342.64 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $265.21 | 2025 | Saphnelo, Breztri, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $221.55 | 2025 | Jardiance, Jascayd |
| Lilly USA, LLC | $213.20 | 2025 | Mounjaro, Zepbound, Jardiance |
| Ucb, INC. | $174.02 | 2025 | Bimzelx |
| Takeda Pharmaceuticals U.S.A., INC. | $144.25 | 2025 | Trintellix, Cuvitru |
| Biocryst US Sales Co., LLC | $135.66 | 2025 | Orladeyo |
| Novo Nordisk INC | $124.70 | 2025 | Ozempic, Rybelsus |
| Abbott Laboratories | $114.63 | 2025 | Freestyle Libre 3 |
| Exact Sciences Corporation | $104.65 | 2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $88.81 | 2025 | Caplyta |
| Mallinckrodt Hospital Products INC. | $84.42 | 2025 | Acthar |
| Amgen INC. | $78.80 | 2025 | Otezla, Prolia, Evenity |
| Pfizer INC. | $60.57 | 2025 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $56.95 | 2025 | Dupixent |
| Ibsa Pharma INC. | $50.71 | 2025 | Tirosint, Licart, Flector |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $43.56 | 2025 | Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $37.14 | 2025 | |
| Glaxosmithkline, LLC. | $33.85 | 2025 | Trelegy Ellipta |
| Axsome Therapeutics, INC. | $29.53 | 2025 | Auvelity |
| Insulet Corporation | $22.72 | 2025 | Omnipod |
| Octapharma USA, INC. | $21.96 | 2025 | Octagam Immune Globulin (Human) |
| Genzyme Corporation | $21.60 | 2025 | |
| Agios Pharmaceuticals, INC. | $21.45 | 2025 | Pyrukynd |
| Biogen, INC. | $19.61 | 2025 | Skyclarys |
| Janssen Biotech, INC. | $18.12 | 2025 | Tremfya |
| Sobi, INC | $17.27 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $16.03 | 2025 | Eliquis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Henry Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.